Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Update: 2025-04-02
Description
Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.
Timecodes
1:35 Individualized Care for PC
9:24 Frailty & Comorbidities in PC
12:27 Molecular Testing in PC
18:10 Sequencing in PC
22:00 Doublets/Triplets in mHSPC
30:00 Subgroups in mHSPC
39:00 ARASENS Subgroup Analysis
43:55 Future of mHSPC Care
Timecodes
1:35 Individualized Care for PC
9:24 Frailty & Comorbidities in PC
12:27 Molecular Testing in PC
18:10 Sequencing in PC
22:00 Doublets/Triplets in mHSPC
30:00 Subgroups in mHSPC
39:00 ARASENS Subgroup Analysis
43:55 Future of mHSPC Care
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
